VANCOUVER, June 16, 2017 /CNW/ - Isodiol International
Inc. (CSE: ISOL) (OTC: LAGBF) (Frankfurt: LB6A.F) (the "Company" or "Isodiol International") a global cannabis
innovator specializing in the development of pharmaceutical and consumer products is pleased to announce the closing of the
second tranche of its non-brokered private placement (the "Private Placement"). The second tranche consisted of the issuance of
15,807,947 units at a price of $0.12 per unit for gross proceeds of $1,896,954 CDN. The Company over subscribed the private placement for a total of $4,142,070 CDN. Each Unit consists of one common share in the capital of the Company (a "Share") and one common
share purchase warrant (a "Warrant") exercisable at $0.25 for a period of two years. All securities
issued are subject to a hold period expiring four months and one day from the date of issuance.
The Company will use the proceeds of the Private Placement primarily for working capital and general corporate purposes,
which may include expansion of growth, research and development.
"We are very excited to complete this financing, with very strong interest from institutional, accredited, existing
and new investors," said Marcos Agramont, Chief Executive Officer of Isodiol Inc. "With this
financing now closed, we move forward with a healthy balance sheet and the ability to execute our vision with a strong financial
support " said Agramont.
About Isodiol International Inc.
Isodiol International, Inc. is the market leader in pharmaceutical grade cannabis compounds and the industry leader in
manufacturing and development of consumer products . Isodiol's nutraceutical division is the
pioneer of many firsts for Hemp-derived cannabidiol (CBD), including 99% pure crystalline isolate, micro-encapsulation, and nano
technology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, seeking joint ventures
and acquisitions to expand its portfolio of brands and subsidiaries and will aggressively continue International expansion into
Latin America, Asia and Europe.
ON BEHALF OF THE BOARD
"Marcos Agramont"
CEO & Director
Join Us On Face Book:
https://www.facebook.com/isodiol/
Twitter: @isodiol
Forward-Looking Information: This news release contains "forward-looking information"
within the meaning of applicable securities laws relating to statements regarding the Company's business, products and future the
Company's business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations
reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be
correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are
subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those
contemplated by these statements depending on, among other things, the risks that the Company's products and plan will vary from
those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required
by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or
forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward
looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no
reference to profitability based on sales reported. The statements in this news release are made as of the date of this
release.
The CSE has not reviewed, approved or disapproved the content of this press release.
SOURCE Isodiol International Inc.
View original content: http://www.newswire.ca/en/releases/archive/June2017/16/c1002.html